The tau-immunoreactive A68 polypeptides found in brains from patients with Alzheimer's disease have been studied by Western blotting using (1) antibodies to synthetic peptides corresponding to sequences that span the complete human tau molecule, and (2) antibodies specific for inserts 1 and 2 found towards the N-terminus of some tau isoforms. The three major A68 polypeptides were labelled by all of the antibodies to sequences common to all tau isoforms, but the fastermigrating A68 polypeptide was not labelled by either of the two antibodies specific for inserts 1 and 2. Treatment with alkaline phosphatase of non-solubilized A68 did not change its electrophoretic mobility on SDS/PAGE under the conditions described here. However, A68 that was solubilized before treating it with alkaline phosphatase was found to move faster on SDS/PAGE than untreated A68, to a position similar to that of normal tau. We also confirmed that A68 preparations contain numerous paired helical filaments (PHF). These PHF were labelled by all anti-tau antibodies, including insert-specific antibodies. Our results further support the notion that PHF contain abnormally phosphorylated tau in an aggregated state, and indicate that these abnormally phosphorylated tau forms are composed of several tau isoforms and that the full length of the tau molecule is present in these polypeptides.
INTRODUCTION
Abnormal filaments with a characteristic ultrastructure [the so-called paired helical filaments (PHF)] accumulate in neurons in Alzheimer's disease to form the neurofibrillary tangle, a characteristic neuropathological lesion of the disease. The number of neurofibrillary tangles is correlated with the severity of dementia. Although the mechanisms of formation of these abnormal filaments have still to be elucidated, something of their biochemical composition is known. Immunological (Brion et al., 1985b Delacourte & Defossez, 1986;  Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Nukina & Ihara, 1986) and biochemical (Wischik et al., 1988b; Kondo et al., 1988; Greenberg & Davies, 1990 ) studies have shown that the microtubule-associated protein tau is a component of PHF.
Tau proteins are a group of developmentally regulated phosphoproteins generated by alternative splicing of a primary transcript originating from a single gene (Couchie & Nunez, 1985; Goedert et al., 1988 Goedert et al., , 1989a Himmler et al., 1989; Himmler, 1989; Kosik et al., 1989; Lee, 1990) . Tau proteins are known to induce the polymerization of microtubules and to stabilize microtubules in vivo (Cleveland et al., 1977; Kanai et al., 1989; Caceres & Kosik, 1990) . Six human tau isoforms are known (Goedert et al., 1989a) , differing by the presence or absence of two types of inserts in the N-terminal half of the molecule (inserts 1 and 2) and each with three or four tandem tubulin-binding repeats in the C terminal domain (Goedert & Jakes, 1990 ).
Abnormalities of tau in Alzheimer's disease might explain the collapse of the microtubule network observed in tangle-bearing neurons in the disease (Dustin & Flament-Durand, 1982) . Tau in Alzheimer's disease has been reported to be abnormally phosphorylated (Grundke-Iqbal et al., 1986b; Iqbal et al., 1989; Ueda et al., 1990) and abnormal forms of tau, e.g. with slower mobility on SDS/PAGE than normal tau, have been described in Alzheimer's disease (Flament et al., 1989; Gache et al., 1990; Hanger et al., 1991) . These slower-migrating tau species in Alzheimer's disease have also been reported to be abnormally phosphorylated (Flament et al., 1989; Hanger et al., 1991) . The abnormal phosphorylation of tau in Alzheimer's disease might be pathophysiologically important, since phosphorylated tau has been observed to be less efficient than dephosphorylated tau in promoting tubulin polymerization (Lindwall & Cole, 1984) .
Several polypeptides in the molecular mass range 60-68 kDa, termed A68 polypeptides, have been described in Alzheimer's disease brain tissue but are absent from control brains; they were initially identified with the Alz5O monoclonal antibody and are thought to be a component of PHF (Wolozin et al., 1986; Ksiezak-Reding et al., 1990) . Alz5O cross-reacts with tau, and A68 polypeptides are labelled by most anti-tau antibodies (Nukina et al., 1987; Ksiezak-Reding et al., 1988 , 1990 Ueda et al., 1990) . Nevertheless, A68 differs in some physico-chemical properties from normal tau, and the relationship between A68 and tau has been a matter of debate. The recent work of Lee et al. (1991) has demonstrated by sequence analysis of some peptides derived from A68 that A68 is derived from tau and in fact appears to be an abnormally phosphorylated form of tau that migrates like tau after treatment with alkaline phosphatase. In other studies it was, however, reported that treatment of A68 with alkaline phosphatase failed to change its electrophoretic mobility (Ksiezak-Reding et al., 1990; Vincent & Davies, 1990) .
In order to probe further the relationship between A68 and tau, we have used a panel of antibodies specific for a range of epitopes that span the complete tau molecule, and two antibodies specific for particular tau isoforms. We have also investigated the discrepancy between reports on the effects of alkaline phosphatase on the mobility of A68 in SDS/PAGE. Our findings demonstrate that intact rather than fragments of tau constitute the A68 protein and that A68 is an aggregated and apparently Abbreviation used: PHF, paired helical filaments.
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EXPERIMENTAL Antibodies
The preparation of antisera to bovine (B19) tau proteins has been described previously Hanger et al., 1991) . Anti-TP1O, -TP20, -TP30, -TP40, -TP50, and -TP60 antisera were prepared against synthetic peptides corresponding to sequences in human tau and have been previously described . These peptides correspond to the following amino acid residues in the longest human tau isoform ( Fig. 1) (Goedert etal., 1989a) : 9-18 (TP1O), 32-41 (TP20), 199-126 (TP30), 212-221 (TP40), [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] and 387-394 (TP60). BR133 and BR134 antisera were raised to synthetic peptides corresponding to the most N-terminal (amino acids 1-16) and the most C-terminal (amino acids 428-441) residues of human tau respectively (Goedert et al., 1989a) . BR200 and BR189 were raised to synthetic peptides corresponding to amino acid residues (a) TP10 (Goedert et al., 1989a) . Tau-l is a monoclonal antibody to tau that labels neurofilbrillary tangles strongly only after alkaline phosphatase treatment (Grundke-Iqbal et al., 1986b) . Alz5O is a monoclonal antibody labelling a 68 kDa species (A68) abundant in Alzheimer's disease brain tissue (Wolozin et al., 1986) . The anti-PHF serum (B4) was raised to fractions enriched in PHF (Brion et al., 1985a) .
Preparation and dephosphorylation of tau and A68 fractions A68 fractions were prepared essentially by the procedure of Ksiezak-Reding et al. (1990) from brain tissue taken post mortem in four normal subjects (aged 61, 65, 66 and 72 years) and from five Alzheimer subjects (aged 60, 70, 81, 82 and 89 years). Brain tissue from the temporal cortex was homogenized (1 g/10 ml) on ice in 10 mM-Tris/HCl (pH 7.4/0.8 M-NaCl/ I mM-EDTA/I0 % (w/v) sucrose. The homogenate was centrifuged for 20 min at 15000 gaV and the supernatant was retained. The pellet was rehomogenized in the same volume and centrifuged as above. The two supernatants were combined and treated with 1 % (w/v) Sarkosyl for 30 min at room temperature. This fraction was then centrifuged for 30 min at 60000 gav.. The supernatant was used as a source of soluble tau proteins and the pellet, constituting the A68 fraction, was washed and resuspended in 50 mM-Tris/HCl, pH 7.5 (0.5 ml/g of starting tissue).
Portions of the A68 preparations were treated for 20 min at room temperature with SDS (2 %, w/v, final) and centrifuged for 2 h at 20000 gav.. The pellet and the supernatant of these SDS-treated A68 preparations were kept for Western blot analysis.
The A68 preparation, the supernatant from the A68 preparation containing normal tau proteins (see above) and the supernatant of SDS-treated A68 preparation were treated directly with calf intestinal alkaline phosphatase (Boehringer, 400 units/ ml) in 50 mM-Tris/HCl, pH 8.3, 50 mM-NaCl, 1 mM-MgCl2, 1 mM-ZnCl2, 1 mM-phenylmethanesulphonyl fluoride, 10 lzg of leupeptin/ml, for 16 h at 37 'C. After this dephosphorylation, the A68 preparation was centrifuged (60 min at 20000 gav) and the pellet was retained. Controls were performed by adding Na2HP04/NaH2PO4, pH 8.3, to a final concentration of 0.2 M in the same incubation solution to inhibit alkaline phosphatase.
The samples were run on SDS/PAGE [10 % (w/v) gels] (Laemmli, 1970) and electrophoretically transferred from gels to nitrocellulose membranes (Towbin et al., 1979) . Nitrocellulose membranes were blocked in semi-fat dried milk (10 %, w/v) for 2 h at room temperature, and incubated for 18 h with the primary antibodies followed by goat anti-rabbit or anti-mouse immunoglobulins conjugated to alkaline phosphatase (Sigma) .
The presence of PHF in these preparations at each step was checked by examining, by electron microscopy, portions adsorbed on formvar-coated grids and negatively stained, with 1 % (w/v) sodium/potassium phosphotungstate. (Goedert & Jakes, 1990) .
Isolated PHF present in A68 preparations and in A68 preparations treated with alkaline phosphatase were adsorbed on formvar-coated grids for electron microscopy and immunolabelled, as previously described (Brion et al., 1985a Mapping of tau epitopes in A68 Fig. 1(a) shows the amino acid sequences of the six known tau isoforms (Goedert et al., 1989a) ; the sequences that were used for raising the specific anti-(tau peptide) antisera are indicated. Fig. 1(b) shows a schematic drawing of the six known human tau isoforms.
The labelling of A68 on Western blots by the various anti-(tau peptide) antisera is shown in Figs. 3(a) and 3(b) . Epitopes that are present in all isoforms of tau and which span the complete tau molecule, including the N-and C-terminal sequences, are present in all three major A68 species (Fig. 3a) ; the intensity of labelling by some antibodies is weaker than others, but this reflects their known lower titres. The monoclonal antibody Alz5O labelled all three A68 species as described by others (Ksiezak-Reding et al., 1990; Lee et al., 1991) . The blots in Fig. 3(a) were not all performed on the same SDS gel/polyacrylamide, so the positions of the bands vary slightly from track to track, but they have been arranged so that the corresponding bands are approximately aligned. The labelling of A68 species by the monoclonal antibody Tau-I required the pretreatment of the A68 fraction with alkaline phosphatase, as reported (Ksiezak-Reding et al., 1990; Lee et al., 1991) . The antisera specific for particular tau isoforms, determined by inserts 1 and 2 located towards the N-terminus of tau (BR189 and BR200), selectively labelled the upper two major A68 species (Fig. 3b) . The lowermost major A68 polypeptide was not labelled by either of these antibodies. The species that migrated more slowly than the uppermost member of the A68 triplet was labelled, but usually only weakly, by antibodies recognizing all tau isoforms and also by BR189; antibody BR200 was not a high-titre reagent, and this probably explains why it did not label this band.
Dephosphorylation of A68 and tau
The A68 fractions were treated with alkaline phosphatase and centrifuged. The pellet contained PHF and the A68 polypeptides. Under the conditions described here, this treatment of A68 fractions with alkaline phosphatase before subjecting them to Immunolabelling in electron microscopy of isolated PHF present in the A68 fraction Labelling was carried out with (a) the TPIO antibody to tau peptide containing residues 9-18, (b) the BR134 antibody to tau peptide 428-411 (the most C-terminal amino acids), (c) the BR200 antibody to tau peptide 61-72 (specific for insert 1), and (d) the BR189 antibody to tau peptide 76-87 (specific for insert 2). Scale bar: 100 nm. SDS/PAGE failed to change the electrophoretic mobility of the A68 polypeptides (Fig. 4, tracks A and B) in four Alzheimer cases, and induced only a minor increase of this mobility in one case. This may be because A68 is an aggregated form of tau, with restricted accessibility of the alkaline phosphatase. The A68 fraction was therefore treated with SDS and centrifuged. The pellet was shown by Western blotting to contain little, if any, A68 (Fig. 4, track C) . The supernatant, containing solubilized A68 (Fig. 4, track D) , was treated with alkaline phosphatase. This solubilized and alkaline phosphatase-treated A68 was found to migrate faster than untreated solubilized A68 (Fig. 4 , tracks D and E). Treatment of solubilized A68 with alkaline phosphatase in the presence of 0.2 M-phosphate did not induce this faster migration ofA68 (results not shown). Soluble tau from Alzheimer or control brains that was treated with alkaline phosphatase before subjecting it to SDS/PAGE migrated faster than untreated tau (results not shown), as noted earlier (Lindwall & Cole, 1984) .
Iminunoelectron microscopy of PHF in the A68 fraction
The panel of antibodies was used to label in the electron microscope the isolated PHF present in the A68 fraction (Fig. 5) A68 proteins are composed of several phosphorylated tau isoforms The PHF were labelled as they were isolated or after pretreatment with alkaline phosphatase. All of the antibodies labelled the PHF, but with some variations in the intensity of labelling ( Fig.  5 and Table 1 ). The insert-specific antibodies BR189 and BR200 gave weaker labelling than other antibodies to epitopes in the Nterminal half of tau (e.g. TPIO) that recognize all tau isoforms. The labelling by Tau-1 was greatly enhanced by alkaline phosphatase treatment (Fig. 6 ).
DISCUSSION
A68 polypeptides are found in brains of subjects with Alzheimer's and some other diseases, but not in control brains (Wolozin et al., 1986; Ksiezak-Reding et al., 1990) . Highly purified A68 preparations were recently observed to contain abundant PHF (Lee et al., 1991) , implying that A68 is a major constituent of PHF. Distinct tau proteins have also been shown to be a constituent of PHF (Greenberg & Davies, 1990) , but despite immunological cross-reactivity between tau and A68, there has been some debate as to whether or not A68 is an abnormal form of tau (Nukina et al., 1987; Ksiezak-Reding et al., 1988; Vincent & Davies, 1990; Lee et al., 1991) . Furthermore, the question of whether the whole of the tau molecule, including all isoforms, is incorporated into PHF has not been answered.
In the present study we have confirmed that preparations of A68 proteins contain abundant PHF. These PHF were decorated by antibodies spanning the whole of the tau sequence, including antibodies specific for inserts 1 and 2. These latter antibodies labelled as many PHF as did other antibodies, indicating that different isoforms of tau are probably not responsible for forming different subpopulations of PHF, but rather that individual PHF contain a mixture of different isoforms.
The A68 proteins migrated on SDS/PAGE as a set of three strongly labelled bands, shown by using antibodies to tau, but there was also a less abundant and slower-migrating form. Bands below the major triplet were weaker and more variable. This pattern is very similar to Western blot patterns described by others (Ksiezak-Reding et al., 1990; Lee et al., 1991) . Western blots of A68 have also shown that epitopes spanning the whole of tau are present in the A68 polypeptides and the monoclonal antibody Alz5O, labelled A68 in a pattern indistinguishable from that produced by the anti-tau antibodies that label all isoforms of tau. We conclude that A68 is an abnormally migrating (on SDS/PAGE) but aggregated form of tau.
The epitope for antibody BR189 is located in insert 2, which is present in the two largest forms of normal tau (Goedert & Jakes, 1990) , and the epitope for antibody BR200 is present in insert 1, which is present in the four largest tau isoforms (Goedert & Jakes, 1990) . These two antibodies labelled the two largest major tau forms of A68. The smallest isoform of A68 was not labelled by either of these tau-isoform-specific antibodies.
These data suggest that the different A68 polypeptides are derived from particular tau isoforms. However, it is not yet possible to decide on the basis of the present findings if all six tau isoforms can be modified to produce A68 polypeptides, or if only three tau isoforms are converted to A68. It seems likely, however, that the smallest major A68 band is derived from tau lacking any inserts towards the N-terminus (inserts 1 and 2). The two major largest A68 species would contain both inserts 1 and 2 and may differ from each other by the presence either of three or four tubulin-binding sites. Protein sequencing studies have shown that both three-and four-tubulin-binding site forms of tau are present in isolated PHF fractions (Kondo et al., 1988; Wischik et al., 1988a) , but it cannot be established from these separate studies how the number of tubulin-binding sites is related to tau forms in A68. An additional minor band which migrated more slowly than the major A68 triplet polypeptides was detected with BR189 in A68 preparations, and might correspond to another tau isoform containing insert 2. However, this minor band was not obviously labelled by antibody BR200 as would be predicted from the pattern of insertions in tau, i.e. isoforms containing insert 2 always contain insert 1 (Goedert et al., 1989a) . The lack of labelling by BR200 is possibly because the staining by this antibody is weaker than that by BR189, rather than indicating a novel splicing of tau in Alzheimer's disease.
Treatment of tau with alkaline phosphatase is known to increase its mobility on SDS/PAGE (Lindwall & Cole, 1984) . We and others have shown that abnormal forms of tau in Alzheimer's disease and Down's syndrome brain extracts have lower mobility on SDS/PAGE than normal tau, but this mobility can be shifted into the normal tau mobility range by alkaline phosphatase treatment of the tau following solubilization in SDS (Flament et al., 1989; Hanger et al., 1991) . A68 has been reported not to shift on SDS/PAGE following treatment with alkaline phosphatase (Ksiezak-Reding et al., 1990; Vincent & Davies, 1990) . We found that the mobility of A68 on SDS/PAGE was increased by alkaline phosphatase treatment under the conditions described here only after the A68 had been solubilized in SDS. This indicates that the lack of effect of alkaline phosphatase on A68 mobility is probably due to the aggregated state of A68.
The labelling of neurofibrillary tangles or PHF by the Tau-1 antibody has been shown to be dependent on prior dephosphorylation (Grundke-Iqbal et al., 1986b; Kosik et al., 1988) . We observed that treatment of A68 preparations with alkaline phosphatase induced unmasking of the Tau-l epitope on PHF found in these preparations. This particular treatment of A68 preparations with alkaline phosphatase does not, however, affect A68 mobility on SDS/PAGE, as discussed above, and so the results suggest that dephosphorylation at a site different from the Tau-1 epitope is necessary to change the mobility of A68 on SDS/PAGE. 
